REPL ▲ +21.1% - Replimune Group, Inc. $REPL Jefferies analyst Roger Song raised the firm's price target on Replimune to $29 from $24 and keeps a Buy rating on the shares. Three weeks post-Tudri launch, roughly 20 accounts have formulary access and more than 15 have prescribed, with management seeing potential to roughly double initiating accounts by year-end 2026, the analyst tells investors in a research note. The firm added that it is encouraged by visceral and regional-center adoption, and remains positive with account conversion, repeat use, and dosing volumes next to watch. 28-OCT-2026 04:43 PM ET